Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents

Cancer Chemotherapy and Pharmacology

Volumn 49, Issue 6, 2002, Pages 479-486

  Barret, Jean Marc ^a   Kruczynski, Anna ^a   Etiévant, Chantal ^a   Hill, Bridget T ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Combination index; Cultured cells; F 11782; In vivo; Synergy

Indexed keywords

2',3' BISPENTAFLUOROPHENOXYACETYL 4',6' ETHYLIDINE BETA DEXTRO GLUCOSIDE; ACLARUBICIN; ANTINEOPLASTIC AGENT; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; F 11782; FLUOROURACIL; GYRASE INHIBITOR; MITOMYCIN C; NAVELBINE; PACLITAXEL; TOPOTECAN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER TRANSPLANTATION; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA SYNTHESIS INHIBITION; DRUG POTENTIATION; EXCISION REPAIR; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA P 388; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; TESTIS TERATOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL SURVIVAL; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MICE; NAPHTHALENES; NEOPLASMS; PYRANS; TUMOR CELLS, CULTURED;

EID: 0036098112     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0451-5     Document Type: Article

References (36)

1. New developments in antitumor anthracyclines
2. In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs
3. Characterization of DNA-strand breakage induced in V79 cells by F 11782, a catalytic inhibitor of topoisomerases
4. Detection of DNA-strand breaks in cells treated with F 11782, a catalytic inhibitor of topoisomerases I and II
5. Inhibition of nucleotide excision repair and sensitisation of cells to DNA cross-linking anticancer drugs by F 11782, a novel fluorinated epipodophylloid
6. Different inherited levels of DNA repair replication in xeroderma pigmentosum cell strains after exposure to ultraviolet irradiation
7. Quantitation analysis of dose-effect relationships: The combined effects of multidrugs or enzyme inhibitors
8. Computerized quantitation of synergism and antagonism of Taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design
9. Topoisomerase-targeting antitumor drugs
10. The development of combination therapy involving camptothecins: A review of preclinical and early clinical studies
11. Vinflunine (20′,20′-difluoro-3′,4′-dihydrovinorelbine), a novel vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro
12. F 11782 a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual inhibitors, intoplicin, aclarubicin and TAS-103
13. The search of synergy: A critical review from a response surface perspective
14. Synthesis and antitumor activity of a novel epipodophylloid: F 11782, a dual inhibitor of topoisomerases I and II
15. Clinical applications of anticancer drugs targeted to topoisomerase II
16. Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines
17. In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines
18. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines
19. New antimetabolites in cancer chemotherapy and their clinical impact
20. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours
21. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated vinca alkaloid
22. Preclinical antitumour activity of F 11782, a novel dual non-intercalating catalytic inhibitor of topoisomerases
23. Decreased nucleotide excision repair activity is associated with in vivo resistance of a P388 leukemia subline to F 11782, a novel dual catalytic inhibitor of topoisomerase I and II
24. Preclinical phase II studies in human tumour xenografts: A European multicenter follow-up study
25. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro
26. A checkerboard method to evaluate interactions between drugs
27. Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines
28. F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerase I and II with an original mechanism of action
29. Covalent DNA-binding drugs
30. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapy
31. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle
32. Antagonistic effect of aclarubicin on camptothecin induced cytotoxicity: Role of topoisomerase
33. Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: A randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group
34. Clinical applications of the camptothecins
35. Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action
36. Preclinical drug development: Rationale and methods